GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Respiratory illnesses like the flu and COVID-19 spread more commonly in the fall and winter months ahead, and doctors in ...

As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Here’s what you need to know. While most people who contract RSV can recover at home, some are sick enough to be admitted to ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

Researchers sought to determine if the RSV vaccine leads to better health outcomes among older adults with IBD.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...